Judith Kelleher-Andersson, Ph.D.
President and Chief Executive Officer (CEO), Director
Dr. Kelleher-Andersson has over twenty years of experience developing small-molecule, central nervous system therapeutics in the biotechnology industry. Prior to founding Neuronascent, she was Director of Drug Development and Research at Neuralstem, Inc., Centaur Pharmaceuticals and Cortex Pharmaceuticals, Inc. She headed the Alzheimer’s disease program in collaboration with Astra-Zeneca while at Centaur, and successfully brought a small-molecule agent to pre-nomination status. She invented a depression therapeutic that completed Phase IIb, while at Neuralstem. Dr. Kelleher-Andersson has over 70 US, European and World patents. She received her Ph.D. in biochemistry from University of Missouri-Columbia and completed post-graduate work at UCLA with a Mental Retardation Fellowship and at University of California, San Francisco in the Neurology Dept.
Kenneth Narducy, Ph.D., MBA
Acting COO, Director
Kenneth W Narducy, PhD, MBA, has spent more than 30 years in research and development at biomedical companies (including Abbott and Schering-Plough and the last 20 years with young biomedical companies). Three of the pharma companies in which he was a senior executive were acquired (Oculex by Allergan for $230 million, Centaur by Renovis [now Evotec] for $47 million, and St Charles Pharmaceuticals by Colby Pharmaceutical Company). Dr Narducy earned his PhD in Physical Organic Chemistry from Ohio State University and his MBA in Marketing and Finance from the University of Chicago.